SDZNY:OTC-Sandoz Group AG (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 44.54

Change

-0.92 (-2.02)%

Market Cap

USD 19.38B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

-4.35 (-2.78%)

USD 71.76B
MKKGY Merck KGaA ADR

-1.28 (-3.99%)

USD 71.76B
TKPHF Takeda Pharmaceutical Co. Ltd.

-0.83 (-3.10%)

USD 44.53B
HLNCF Haleon plc

+0.01 (+0.23%)

USD 43.64B
TEVJF Teva Pharmaceutical Industries..

+1.86 (+10.33%)

USD 20.99B
SDZXF Sandoz Group AG

N/A

USD 19.52B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 13.26B
SWOBY Swedish Orphan Biovitrum AB (p..

+1.98 (+13.01%)

USD 10.70B
IPSEF Ipsen S.A

N/A

USD 10.37B
IPSEY Ipsen SA ADR

+0.51 (+1.77%)

USD 10.31B

ETFs Containing SDZNY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.14% 71% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.14% 71% C- 76% C+
Trailing 12 Months  
Capital Gain 53.53% 73% C 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.53% 73% C 78% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.84% 58% F 46% F
Dividend Return 4.84% 57% F 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.13% 98% N/A 91% A-
Risk Adjusted Return 29.99% 84% B 65% D
Market Capitalization 19.38B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.